利肺片联合丙酸倍氯米松治疗慢性支气管炎急性发作的临床研究  

Clinical study on Lifei Tablets combined with beclomethasone propionate in treatment of acute attack of chronic bronchitis

作　　者：原全利 高桂梅 闫娇娇 王桂荣 于露露 齐林[3] 李钰兰 YUAN Quan-li;GAO Gui-mei;YAN Jiao-jiao;WANG Gui-rong;YU Lu-lu;QI Lin;LI Yu-lan(Department of Pharmacy,Jiaozuo Fifth People’s Hospital,Jiaozuo 454000,China;Medical Insurance Office,Jiaozuo Fifth People’s Hospital,Jiaozuo 454000,China;Department of Respiratory Medicine,the 7th People’s Hospital of Zhengzhou,Zhengzhou 450016,China;Department of Respiratory Medicine,Jiaozuo Fifth People’s Hospital,Jiaozuo 454000,China)

机构地区：[1]焦作市第五人民医院药剂科,河南焦作454000 [2]焦作市第五人民医院医保办,河南焦作454000 [3]郑州市第七人民医院呼吸科,河南郑州450016 [4]焦作市第五人民医院呼吸科,河南焦作454000

出　　处：《现代药物与临床》2021年第11期2304-2308,共5页Drugs & Clinic

基　　金：河南省医学科技攻关项目(2018020858)。

摘　　要：目的探讨利肺片联合丙酸倍氯米松吸入气雾剂治疗慢性支气管炎急性发作患者的临床疗效。方法选取2019年6月—2021年6月在焦作市第五人民医院就诊的100例慢性支气管肺炎患者,按照随机数字表法将全部患者分为对照组和治疗组,各包括50例患者。对照组使用丙酸倍氯米松吸入气雾剂,100μg/次,3次/d。治疗组在对照组基础上口服利肺片,0.5 g/次,3次/d。两组连续治疗2周后统计疗效。观察两组治疗后的临床疗效,比较两组的主要症状体征消失时间、用力肺活量(FVC)、呼气峰值流速(PEF)、第一秒用力呼气量占用力肺活量比值(FEV1/FVC)以及患者治疗前后痰液中白细胞介素-6(IL-6)、C反应蛋白(CRP)、可溶性髓样细胞触发性受体-1(sTREM-1)水平。结果治疗后,治疗组患者的总有效率(94.00%)明显比对照组的总有效率(80.00%)高(P<0.05)。治疗后,治疗组的止咳时间、平喘时间、痰消时间短于对照组,差异有统计学意义(P<0.05)。治疗后,两组的FVC、PEF、FEV1/FVC均明显升高(P<0.05);且以治疗组FVC、PEF、FEV1/FVC升高更明显(P<0.05)。治疗后,两组的痰液中IL-6、CRP、sTREM-1水平显著降低(P<0.05);且以治疗组痰液中IL-6、CRP、sTREM-1水平降低更明显(P<0.05)。结论利肺片联合丙酸倍氯米松吸入气雾剂治疗慢性支气管炎的疗效确切,能改善患者临床症状和肺功能,减轻肺部炎症反应,且安全性较好。Objective To investigate the clinical efficacy of Lifei Tablets combined with Beclometasone Dipropionate Inhalation Aerosol in treatment of acute attack of chronic bronchitis. Methods Patients(100 cases) with acute attack of chronic bronchitis in Jiaozuo Fifth People’s Hospital from June 2019 to June 2021 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were given Beclometasone Dipropionate Inhalation Aerosol, 100 μg/time, three times daily.Patients in the treatment group were po administered with Lifei Tablets on the basis of the control group, 0.5 g/time, three times daily.Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and the disappearance times of main symptom, FVC, PEF, FEV1/FVC, and the levels of IL-6, CRP, and sTREM-1 in two groups were compared. Results After treatment, total effective rate of the treatment group(94.00%) was significantly higher than that of the control group(80.00%)(P <0.05). After treatment, the cough relieving time, asthma relieving time and phlegm eliminating time in the treatment group were shorter than those in the control group(P < 0.05). After treatment, the FVC, PEF, and FEV1/FVC of two groups were significantly increased(P < 0.05), and the FVC, PEF, and FEV1/FVC in the treatment group were significantly higher than those in the control groups(P <0.05). After treatment, the levels of IL-6, CRP, and sTREM-1 in sputum of two groups were significantly decreased(P < 0.05). The levels of IL-6, CRP, and sTREM-1 in sputum of the treatment group were significantly lower than those in the control group(P < 0.05).Conclusion Lifei Tablets combined with Beclometasone Dipropionate Inhalation Aerosol is effective in the treatment of acute attack of chronic bronchitis, can improve clinical symptoms and pulmonary function, reduce inflammatory reaction, with good safety.

关 键 词：利肺片 丙酸倍氯米松吸入气雾剂 慢性支气管炎急性发作 主要症状体征消失时间 肺功能 炎症因子 

分 类 号：R974[医药卫生—药品]